FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03841110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.
Study identification
- NCT ID
- NCT03841110
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 37 participants
Conditions and interventions
Conditions
- Advanced Solid Tumors
- Lymphoma
- Gastric Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Squamous Cell Carcinoma
- EGFR Positive Solid Tumor
- HER2-positive Breast Cancer
- Hepatocellular Carcinoma
- Small Cell Lung Cancer
- Renal Cell Carcinoma
- Pancreas Cancer
- Melanoma
- NSCLC
- Urothelial Carcinoma
- Cervical Cancer
- Microsatellite Instability
- Merkel Cell Carcinoma
Interventions
- FT500 Drug
- Nivolumab Drug
- Pembrolizumab Drug
- Atezolizumab Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- IL-2 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2019 (Actual)
- Primary completion
- Nov 15, 2022 (Actual)
- Completion
- Nov 15, 2022 (Actual)
- Last update posted
- May 1, 2023
2019 – 2022
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Moores Cancer Center | San Diego | California | 92093 | — |
| University of Minnesota Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Hackensack University Medical Center/John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03841110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2023 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03841110 live on ClinicalTrials.gov.